Anavex Life Sciences Corp. Share Price & Technical Analysis
AVXL · $2.71 (-1.45%)
Healthcare / Biotechnology
$2.71
-1.45%
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), ha…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-18% return in May, 1% avg return in past 3 year May month.
-13% return in 2026, 7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 31% | -4% | -28% | 6% | -18% | – | – | – | – | – | – | – | -13% |
| 25 | -18% | -12% | 8% | 10% | -20% | 23% | 24% | -13% | -6% | -10% | -52% | -5% | -72% |
| 24 | 2% | -15% | -2% | -27% | 11% | 0% | 62% | -12% | -5% | 18% | 40% | 13% | 83% |
| 23 | 10% | -13% | -9% | -5% | 14% | -12% | 1% | -4% | -16% | -15% | 29% | 29% | 8% |
| 22 | -25% | -10% | 13% | -31% | 6% | 9% | 3% | -11% | 8% | 15% | -28% | 4% | -46% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$281.26M
P/E ratio
—
52W high
$13.99
52W low
$2.61
Volume
9,45,910
Beta
1.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Anavex Life Sciences Corp. share price today?
- Anavex Life Sciences Corp. (AVXL) last traded around $2.71 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AVXL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AVXL. Download the app for real-time alerts.
- How can I analyze Anavex Life Sciences Corp. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.